Medical Devices

31 tickers rated Hold in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Koninklijke Philips N.V.
PHG·Healthcare
B ★★★Hold
Current$30.51
Target$34.08
Return+11.7%
Nov 6, 2026

Philips offers exposure to improving medical technology demand and a credible margin recovery at a reasonable normalized valuation, but Respironics liabilities and modest returns on capital constrain its rerating potential.

Score
67
Revvity, Inc.
RVTY·Healthcare
B ★★★Hold
Current$150.83
Target$152.50
Return+1.1%
Nov 6, 2026

Revvity's specialized life-sciences and diagnostics franchises offer improving organic growth and strong cash generation, but elevated valuation multiples and weak reported returns on capital limit near-term upside.

Score
69
Waters Corporation
WAT·Healthcare
B ★★★Hold
Current$453.08
Target$472.50
Return+4.3%
Nov 6, 2026

Waters combines durable laboratory instrumentation, recurring consumables, and expanding diagnostics exposure with meaningful synergy opportunities, but elevated leverage and demanding cash-flow expectations limit its near-term investment appeal.

Score
68
Grifols, S.A.
GRFS·Healthcare
B ★★★Hold
Current$8.60
Target$10.50
Return+22.1%
Nov 5, 2026

Grifols combines durable plasma-derived medicine demand with improving cash flow and deleveraging potential, but substantial debt, capital intensity, and Chinese albumin weakness constrain its valuation recovery.

Score
69
Glaukos Corporation
GKOS·Healthcare
B ★★★Hold
Current$237.60
Target$208.45
Return-12.3%
Nov 2, 2026

Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Score
70
West Pharmaceutical Services, Inc.
WST·Healthcare
B ★★★Hold
Current$412.62
Target$388.74
Return-5.8%
Nov 1, 2026

West Pharmaceutical Services benefits from entrenched pharmaceutical containment relationships and rising demand for premium injectable components, but its elevated valuation requires sustained growth and stronger cash conversion.

Score
69
Illumina, Inc.
ILMN·Healthcare
B ★★★Hold
Current$235.99
Target$210.00
Return-11.0%
Nov 1, 2026

Illumina's entrenched sequencing ecosystem and improving cash generation offer long-term growth potential, but demanding valuation, China restrictions and competitive technology risks constrain near-term upside.

Score
67
Baxter International Inc.
BAX·Healthcare
B ★★★Hold
Current$23.00
Target$27.30
Return+18.7%
Nov 1, 2026

Baxter offers a discounted medical-products turnaround supported by recurring hospital demand, recovering cash flow and debt reduction, but elevated leverage and uncertain margin sustainability limit near-term conviction.

Score
72
Establishment Labs Holdings Inc.
ESTA·Healthcare
B ★★★Hold
Current$62.46
Target$71.20
Return+14.0%
Oct 31, 2026

Establishment Labs can compound revenue through U.S. Motiva adoption and minimally invasive innovation, but its premium valuation, substantial debt, and unproven cash-flow durability limit the margin of safety.

Score
70
Mirion Technologies, Inc.
MIR·Industrials
B ★★★Hold
Current$18.37
Target$20.10
Return+9.4%
Oct 31, 2026

Mirion benefits from long-term nuclear safety and radiation technology demand, supported by accelerating orders and cash generation, but acquisition-related dilution, leverage, and a demanding earnings multiple limit near-term upside.

Score
67
Bausch + Lomb Corporation
BLCO·Healthcare
B ★★★Hold
Current$20.00
Target$21.24
Return+6.2%
Oct 31, 2026

Bausch + Lomb's established eye health franchise and improving premium product mix support earnings recovery, but substantial leverage, weak historical cash conversion and controlling-shareholder uncertainty limit investment upside.

Score
66